Revisiting Psychedelic Drugs for Therapeutic Use
Renewed interest in psychedelics to treat depression and PTSD.
An MDMA therapy session is conducted by researchers Marcela Ot’alora, MA, LPC, and Bruce Poulter, MPH, RN. Photo courtesy of the Multidisciplinary Association for Psychedelic Studies.
As the saying goes, “everything that’s old is new again,” and that apparently applies to the exploration of using psychedelic medications as part of mental health therapy. That’s the topic of one of our feature articles in the June issue.
When I was an ED nurse in the early 1970s, we often saw patients who were brought in because they were on a “bad trips” from illicit use of psychedelic drugs: acid (LSD, lysergic acid diethylamide), but also mescaline (3,4,5-trimethoxyphenethylamine, a hallucinogen derived from the peyote plant), or “magic mushrooms,” which contained psilocybin.
While these drugs were used in in psychiatric research as early as the 1950s (see the AJN article from 1964, “Supporting the Patient on LSD Day,” free until the end of June), they were later banned for use in the 1970s under the Controlled Substances Act after they became popular illicit drugs in the […]